A summary in the April 15 edition of AANP SmartBrief gave the incorrect name of the drug that showed the lowest risk of new-onset diabetes for participants in a meta-analysis. The name of the drug is pravastatin. SmartBrief regrets the error.
A New Zealand meta-analysis that included data from 24 trials found that acute pancreatitis was linked to nearly twice the risk of developing diabetes. Study author Dr. Maxim Petrov said the high rate of new-onset diabetes after a bout of AP shows the need for better prevention and screening strategies.
Canadian researchers found atorvastatin was associated with a 22% increased risk of new-onset diabetes, while patients who took rosuvastatin or simvastatin had an 18% and 10% increased risk of the condition, respectively, compared with patients taking pravastatin. Pravastatin, fluvastatin and lovastatin were tied to a slightly lower diabetes risk, researchers reported in BMJ.
NH2-terminal probrain natriuretic peptide values of greater than 91 pg/mL were associated with an increased risk of all-cause and cardiovascular mortality in older type 2 diabetes patients, including those without a history of heart disease, a study showed. Patients with modest increases in NT-proBNP and those who did not have microalbuminuria and cardiovascular disease at baseline also showed higher mortality risks, researchers wrote in Diabetes Care.
Nurse practitioner and trauma program manager Joe Blansfield of Boston Medical Center said his year serving in Iraq helped him during his work with the victims of the Boston Marathon bombing. Last week's experience was "disturbingly similar," he said. "The lessons learned in Iraq definitely paid dividends on Monday," said Blansfield, who was a colonel in the Nurse Corps of the Army Reserve.
Participants taking plavastatin showed the lowest risk of new-onset diabetes, while atorvastatin and rosuvastatin were associated with intermediate and higher risk, compared with people in a placebo group, a meta-analysis in The American Journal of Cardiology revealed.